Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase II Study of Saruparib in Patients With Platinum-Sensitive, HRDsig+ Solid Tumors

The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency …

Malignant Neoplastic Disease (Disorder)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Abramson Cancer Center at Penn MedicineNCT07832630